Health product safety alerts
Safety alerts and advisories from Canada and other countries all in one place.
Countries
⇡ Canada
Health Canada – Recalls and safety alerts for healthcare professionals
Health Canada – Recalls and safety alerts for the public
⇡ United States
MedWatch Safety Alerts (human medical products):
⇡ France
⇡ UK
- Rarely, severe adverse effects can occur on stopping treatment with topical corticosteroids, often after long-term continuous or inappropriate use of moderate to high potency products. To reduce the risks of these events, pr…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the August 2021 issue of Drug Safety Update, up to 9 September 2021.
- A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
- Recent information relating to COVID-19 vaccines that has been published since the July 2021 issue of Drug Safety Update.
- A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
- Following a review of the available toxicological data and a calculation of daily exposure to boron from a typical dosing regimen, we have concluded that the balance between the benefits and risks of chloramphenicol eye drop…
- If an adverse drug reaction is suspected, ask patients if they are taking any herbal or homeopathic medicines and report any suspicions to the Yellow Card scheme. Remind patients to check that a herbal or homeopathic medicin…
- We have published guidance about the use of remote consultations for pregnancy prevention in women of childbearing potential and monitoring for signs of psychiatric reactions (especially depression) and other safety risks in…
- Revisions have been made to the information for healthcare professionals and information for UK vaccine recipients for the COVID-19 Vaccine Moderna and Pfizer/BioNTech COVID-19 vaccine following a thorough review of ext…
- A summary of letters and drug alerts recently sent to healthcare professionals.
⇡ Australia
- Erenumab and hypertension9 September 2021 Health professionals are advised that the Product Information (PI) for erenumab has been updated with a warning statement about a potential causal relationship between the drug and hypertension.
- Propylthiouracil and carbimazole – use in pregnancy15 September 2021 Health professionals are advised that the pregnancy category for both propylthiouracil and carbimazole is being changed from category C to category D.
- Minocycline and agranulocytosis30 August 2021 Health professionals are advised that the Product Information (PI) for minocycline is in the process of being updated to include information about agranulocytosis, a rare but potentially life-threatening adverse event.
- Parenteral iron products and foetal bradycardia/Kounis syndrome26 July 2021 There are four parenteral iron products marketed in Australia. They are ferric carboxymaltose, iron polymaltose, ferric derisomaltose and iron sucrose.
- Nifedipine and pulmonary oedema when used in pregnancy26 July 2021 The Product Information for nifedipine has been updated to provide new information about the risk of acute pulmonary oedema when used as a tocolytic agent (inhibiting myometrial smooth muscle contractions) for the treatment of preterm labor in pregnancy.
- Ocrelizumab and late onset neutropenia26 July 2021 The Product Information for ocrelizumab has been updated to include a warning and further information about late onset neutropenia.
- Methylphenidate – use in pregnancy22 July 2021 Health professionals are advised that the Product Information (PI) documents for methylphenidate products have been updated with new information about use in pregnancy.
- Bupropion and serotonin syndrome2 July 2021 Health professionals are advised that the Product Information (PI) documents for bupropion-containing products have been updated to include a warning about the risk of serotonin syndrome when this drug is co-administered with other drugs known to be associated with serotonin syndrome, including selective serotonin reuptake inhibitors (SSRIs) and serotonin […]
- Updated contraception advice for tamoxifen23 June 2021 The recommended duration of contraception after finishing tamoxifen treatment has been extended from two months to nine months. This means women should continue their contraception and not become pregnant for at least nine months after tamoxifen therapy has ended.
- Sertraline and microscopic colitis23 June 2021 Health professionals are advised that the Product Information (PI) documents for sertraline have been updated to include microscopic colitis as a potential adverse effect of unknown frequency based on post-marketing experience.
⇡ New Zealand
- Risks of importing or prescribing ivermectin for prevention or treatment of COVID-19
- Dihydrocodeine: review of risks and benefits
- Myocarditis and pericarditis – rare adverse reactions to Comirnaty (Pfizer COVID-19 vaccine)
- Myocarditis – a potential adverse reaction to Comirnaty (Pfizer COVID-19 vaccine)
- Pregabalin and the possible risk of bullous dermatitis and exfoliating skin reactions
- Fluad Quad – a newly funded influenza vaccine for people aged 65 years and older
- COVID-19 vaccines and rare cases of blood clots with bleeding: no current risk with Comirnarty (Pfizer/ BioNTech) vaccine
- UPDATE: Possible risk of psoriasis exacerbation with bupropion
- UPDATE: Concern reported with the use of NovoRapid®Penfill® (insulin aspart; 3 mL cartridge) by type 1 diabetes patients
- UPDATE – Rocuronium bromide solution for injection 10mg/mL, Hameln, and reports of lack of efficacy
